| Document |
Document Title |
|
WO/2016/017422A1 |
Disclosed are a crosslinking nucleoside and nucleotide. This nucleoside has a 2',4'-crosslinking structure, and is represented by formula (I) or (I'). An oligonucleotide containing this 2',4'-crosslinking artificial nucleotide exhibits a...
|
|
WO/2016/016865A1 |
The present invention pertains to process for preparing nucleoside phosphoramidate and its intermediate. The present invention provides novel intermediate, its process for preparation and its use for the preparation of Sofosbuvir.
|
|
WO/2016/016447A1 |
A process for the preparation of a compound of formula (I) including all isomers, stereoisomers, enantiomers and diastereomers thereof (I), and salts thereof; the process comprising providing a mixture comprising a compound of formula (I...
|
|
WO/2016/012781A1 |
The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.
|
|
WO/2016/014927A2 |
Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide ribo...
|
|
WO/2016/008461A1 |
The crystalline Form Z-1 of sofosbuvir, characterized by the following diffraction peaks: 8.0; 12.3; 17.1; 19.9 and 20.8 ±0,2° 2-theta with the use of CuKα radiation, and a method of its preparation.
|
|
WO/2016/011360A1 |
The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sens...
|
|
WO/2015/200216A1 |
Disclosed herein are methods of preparing a phosphoroamidate nucleotide anal which are useful in treating diseases and/'or conditions such as viral infections.
|
|
WO/2015/198058A1 |
Prodrug This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate when present as a single phosphate d...
|
|
WO/2015/198059A1 |
This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations wh...
|
|
WO/2015/188782A1 |
The present invention relates to a method for preparing sofosbuvir. In particular, provided in the present invention is a more stereoselective preparation method. The preparation method has the advantages of a richer required isomer prep...
|
|
WO/2015/185565A1 |
A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...
|
|
WO/2015/186068A1 |
Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicot...
|
|
WO/2015/186114A1 |
Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analo...
|
|
WO/2015/181624A2 |
Provided herein are compounds, compositions, and methods for the treatment of cancer, including leukemia. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in...
|
|
WO/2015/181201A1 |
A composition comprising a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cy...
|
|
WO/2015/176542A1 |
Disclosed are an adenosine derivative as represented by formula I, and synthesis preparation process and use thereof in treating hyperlipidemia, fatty liver and atherosclerosis. Particularly, disclosed is a novel compound N6-(1-(4-methox...
|
|
WO/2015/179284A1 |
This disclosure is related to a method for determining the identity of a nucleotide residue of a single- stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide ...
|
|
WO/2015/178265A1 |
It was discovered that interposing a suitable aromatic amidation linker in making a prodrug to serve as a γ-glutamylation drug provides stability even in a close to physiological environment, recognition by GGT, and very rapid release o...
|
|
WO/2015/168172A1 |
The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, ...
|
|
WO/2015/167620A1 |
The present invention generally relates to compounds that include one or more thermally labile protecting groups, compositions including the compounds, methods of making the compounds and compositions and methods of using the compounds a...
|
|
WO/2015/167616A1 |
Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of pre...
|
|
WO/2015/168461A2 |
Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase ...
|
|
WO/2015/164812A1 |
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and ca...
|
|
WO/2015/162130A1 |
The present disclosure provides novel compounds containing a base- modified nucleoside of formula and methods for detecting the presence of guanine in a nucleic acid and for isolating O6-alkyl guanine comprising nucleic acid. The disclos...
|
|
WO/2015/164770A1 |
Colorimetry is used to detect amplification reaction products. A sample is contacted with a reaction mix under conditions such that an amplification reaction occurs and produces an amplification reaction product if the sample contains a ...
|
|
WO/2015/164573A1 |
Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
|
|
WO/2015/158913A1 |
The present invention relates to novel phosphate-modified nucleosides, such as phosphoramidate nucleosides. The invention also relates to the use of these novel phosphate-modified nucleosides to treat or prevent viral infections and prol...
|
|
WO/2015/161137A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/155739A1 |
The present application discloses a stereoselective process for the preparation of β-C-arylglucosides that does not require the use of conventional carbohydrate protecting groups.
|
|
WO/2015/153496A1 |
Disclosed are modified thymine bases that provide enhanced base-pairing affinity for adenine or 2,6-diaminopurine bases in polynucleotide hybridization complexes. Also disclosed are polynucleotide oligomers, polynucleotide hybridization ...
|
|
WO/2015/148746A1 |
The present invention is directed to 4'-substituted nucleoside derivatives of Formula I (Formula I), and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, an...
|
|
WO/2015/144282A1 |
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.
|
|
WO/2015/148402A1 |
This disclosure provides systems and methods for attaching nano pore-detectable tags to nucleotides. The disclosure also provides methods for sequencing nucleic acids using the disdosed tagged nudeotides. Provided herein are nudeotides w...
|
|
WO/2015/148522A1 |
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition ...
|
|
WO/2015/143712A1 |
Provided is 4'-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and dela...
|
|
WO/2015/139602A1 |
Disclosed are 2'-substituted-2,2'-dehydrated uridine or 2'-substituted-2,2'-dehydrated cytidine compounds as represented by the following general formula I and preparation method thereof. The present invention also relates to a method of...
|
|
WO/2015/137121A1 |
Provided is a means for producing a non-natural nucleoside analog in which position 5 is a hydroxyl group and which is for synthesizing a triazole linking-type non-natural nucleotide having a structure bonded via organic groups containin...
|
|
WO/2015/133491A1 |
Provided are: an oligonucleotide having, at 5'-terminal thereof, a nucleotide or nucleoside residue represented by formula (I) {wherein X1 represents an oxygen atom or the like; R1 represents formula (IIA) (wherein R5A represents a halog...
|
|
WO/2015/133411A1 |
The purpose of the present invention is to search for: a free acid crystal of 3',5'-cyclic diguanylic acid, which does not contain a salt with a metal such as cobalt and magnesium; and a method for producing the crystal in a simple manne...
|
|
WO/2015/134780A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/134334A1 |
Gemcitabine analogs, including monophosphorylated analogs, are described herein and are suitable for use in pharmaceutical compositions, kits and treatment methods. The treatment methods include treatment of viral infections, including, ...
|
|
WO/2015/132577A1 |
The invention relates to compounds for use in the modification of compounds comprising nucleic acid sequences (such as oligonucleotides or the like), to modified oligonucleotides, to the delivery of modified oligonucleotides to cells and...
|
|
WO/2015/125845A1 |
Provided are: a oligonucleotide having at least one bond represented by formula (I): (in the formula, Q is S or O, X1 does not exist, or is a substituted or unsubstituted alkylene in which O may be interposed, X2 is a substituted or unsu...
|
|
WO/2015/125783A1 |
Disclosed are a crosslinked nucleoside and nucleotide. The nucleoside has a 2',4'-crosslinked structure, and is represented by formula (I). An oligonucleotide containing a 2',4'-crosslinked artificial nucleotide according to the present ...
|
|
WO/2015/126995A1 |
The present disclosure encompasses solid state forms of Sofosbuvir and pharmaceutical compositions thereof.
|
|
WO/2015/120237A2 |
The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Infl...
|
|
WO/2015/120065A1 |
A method of reducing a subject's plasma triglyceride level, comprising administering to a subject in need thereof a gamma-secretase inhibitor in an amount effective to reduce the subject' s plasma triglyceride level.
|
|
WO/2015/112014A1 |
The present invention relates to a process comprising the step of reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein: a (hetero)aryl 1,3-dipole compound is defined as a compound comprising a 1,3-dipole functi...
|
|
WO/2015/112013A1 |
The present invention relates to a process for attaching an N-acetylgalactosamine- (hetero)arylmoiety to an N-acetylglucosaminemoiety, the process comprising the step of contacting the N-acetylgalactosamine-(hetero)arylmoiety with the N-...
|
